Biocon share price falls 3% after Health Ministry gives a pass to its COVID-19 drug
A majority of the members of the task force opined that there was not enough evidence currently to get the drug included in the clinical management protocols for COVID-19, sources said.
BIOCON LTD. - 532523 - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Biocon Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here BIOCON LTD. - 532523 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Voting results and scrutinizers' report of the 42nd Annual General Meeting ('AGM') of Biocon Limited ('the Company') BIOCON LTD. - 532523 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Outcome of 42nd AGM of Biocon Limited - Proceedings Itolizumab to be a blockbuster opportunity for Biocon: Kiran Mazumdar-Shaw
We felt that this was the drug that would actually have a role to play in dealing with the cytokine storm that is being seen in Covid-19 patients, says Shaw
Higher expenses shrink Biocon's Q1 profits stock's valuation banks on launches
Research and development expenses in Q1 jumped about 35% .Material costs too were substantially higher, impacting even gross margins
Earnings Call Transcript - Q1FY21 for Biocon
Conference Call with Biocon Management and Analysts on Q1FY21 Performance and Outlook. Listen to the full earnings transcript. BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Biocon Q1FY21 Revenue Rs 1,690 Cr, Up 14%; EBITDA at Rs 432 Cr; Net Profit (from continuing ops) at Rs 153 Cr, Generics up 16% at Rs 599 Cr, Biosimilars up 19% at Rs 692 Cr. BIOCON LTD. - 532523 - Financial Results For The Quarter Ended June 30, 2020.
Pursuant to Regulation 30 and 33 of SEBI (Listing Obligation and Disclosure Requirements) 2015, we wish to inform you that the Board of Directors at its meeting held today, has considered and approved the unaudited financial results (consolidated and standalone) as per Indian Accounting Standard (Ind-AS) along with Limited Review Report for the quarter ended June 30, 2020. A copy of the un-audited financial results along with the Limited Review Report is enclosed herewith. The above information will also be available on the website of the Company at www.biocon.com. Further, the Board Meeting commenced at 8:30 pm and concluded at 10:50 pm. BIOCON LTD. - 532523 - Financial Results For The Quarter Ended June 30, 2020
Pursuant to Regulation 30 and 33 of SEBI (Listing Obligation and Disclosure Requirements) 2015, we wish to inform you that the Board of Directors at its meeting held today, has considered and approved the un-audited financial results (consolidated and standalone) as per Indian Accounting Standard (Ind-AS) along with Limited Review Report for the quarter ended June 30, 2020. A copy of the un-audited financial results along with the Limited Review Report is enclosed herewith. The above information will also be available on the website of the Company at www.biocon.com. Further, the Board Meeting commenced at 8:15 pm and concluded at 10:50 pm.